Following an injunction by the U.S. District Court, Edwards Lifesciences' acquisition of JenaValve Technology has been blocked.
As a result of the court ruling, Edwards will not proceed with the planned acquisition of JenaValve.
Despite this setback, Edwards Lifesciences reaffirms its commitment to advancing aortic valve replacement (AR) therapy and pioneering innovative treatments for patients.
Acquisition Block
The U.S. District Court injunction hinders Edwards Lifesciences from completing the acquisition of JenaValve, altering its strategic trajectory.
Commitment to Patients
Edwards remains focused on enhancing AR therapy and introducing groundbreaking therapies to address patient needs in the structural heart space.
Financial Guidance Update
Edwards Lifesciences has adjusted its full-year 2026 adjusted EPS guidance to a range of $2.90 to $3.05, reflecting the impact of the halted acquisition.
- The regulatory intervention disrupts Edwards' expansion plans, necessitating a reassessment of its growth strategies.
- With the JenaValve acquisition off the table, Edwards must explore alternative pathways to maintain its leadership in AR therapy and drive therapeutic innovations in the structural heart market.
Despite the regulatory obstacle presented by the injunction, Edwards Lifesciences stands steadfast in its mission to advance patient care through innovative therapies, resilient in the face of strategic challenges.